Knowledge Hub

Popular Market Report: Adenosine Receptor A3 (ADORA3) - Pipeline Review, H1 2016

Press release   •   Jul 18, 2016 07:13 EDT

Global Markets Directs, Adenosine Receptor A3 (ADORA3) - Pipeline Review, H1 2016, provides in depth analysis on Adenosine Receptor A3 (ADORA3) targeted pipeline therapeutics.

The report provides comprehensive information on the Adenosine Receptor A3 (ADORA3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Download Sample copy of this Report at


- The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)

- The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects

- The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Follow us on LinkedIn:

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Adenosine Receptor A3 (ADORA3) Overview 6

Therapeutics Development 7

Adenosine Receptor A3 (ADORA3) - Products under Development by Stage of Development 7

Adenosine Receptor A3 (ADORA3) - Products under Development by Therapy Area 8

Adenosine Receptor A3 (ADORA3) - Products under Development by Indication 9

Adenosine Receptor A3 (ADORA3) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Adenosine Receptor A3 (ADORA3) - Products under Development by Companies 13

Adenosine Receptor A3 (ADORA3) - Products under Development by Universities/Institutes 15

Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development 23

Can-Fite BioPharma Ltd. 23

Huons Co., Ltd. 24

Adenosine Receptor A3 (ADORA3) - Drug Profiles 25

ACN-1052 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

CF-102 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

CF-602 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

HU-010 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

LJ-1888 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

PBF-1472 - Drug Profile 34

Product Description 34

Mechanism Of Action 34 is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.